ALB and neoplasm: The advent of nanotechnology in oncology drug delivery catalyzed the development of nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a formulation designed to circumvent these limitations by leveraging endogenous albumin pathways for enhanced tumor-specific accumulation (6).